Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Downgrades Fortis to Neutral, Announces C$61 Price Target

UBS analyst Ross Fowler downgrades Fortis (TSX:FTS) from Buy to Neutral and announces C$61 price target.

byBenzinga Newsdesk

January 5, 2022

1 minute read

UBS analyst Ross Fowler downgrades Fortis (TSX:FTS) from Buy to Neutral and announces C$61 price target.

INmune Bio Reports Combination Therapy With INB03™ Overcomes Resistance To Trastuzumab-Deruxtecan In MUC4 Expressing HER2+ Breast Cancer

By Benzinga Newsdesk

Today, 2:28 AM

Neutralizing soluble TNF with INB03™ overcomes resistance to trastuzumab-deruxtecan in MUC4 expressing HER2+breast cancer. Combination therapy of INB03™ and trastuzumab-deruxtecan presented at the 45th

INMB

Morgan Stanley Maintains Underweight on C.H. Robinson Worldwide, Raises Price Target to $67

By Benzinga Newsdesk

Today, 2:28 AM

Morgan Stanley analyst Ravi Shanker maintains C.H. Robinson Worldwide (NASDAQ:CHRW) with a Underweight and raises the price target from $66 to $67.

CHRW

Analyst Ratings

Analyst Ratings For Enerpac Tool Group

By Benzinga Insights

Today, 2:28 AM

Analysts have provided the following ratings for Enerpac Tool Group (NYSE:EPAC) within the last quarter:

EPAC

The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal

By Shanthi Rexaline

Today, 2:28 AM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23)

ABBV

UBS Downgrades Fortis to Neutral, Announces C$61 Price Target

Related Posts

INmune Bio Reports Combination Therapy With INB03™ Overcomes Resistance To Trastuzumab-Deruxtecan In MUC4 Expressing HER2+ Breast Cancer

Morgan Stanley Maintains Underweight on C.H. Robinson Worldwide, Raises Price Target to $67

Analyst Ratings For Enerpac Tool Group

The Daily Biotech Pulse: Cara’s Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal